ondasdechoque.org
PT-BR

Post-stroke spasticity and motor function · Randomized trial · 2026

Does shockwave help arm movement after a stroke?

Yes, in this trial. People who added radial shockwave to their usual physiotherapy regained more arm movement and reported a better quality of life than with physiotherapy alone. The gains were still there at 18 weeks.

Helped more than physiotherapy alone
people recovering from a stroke
120
sessions over 6 weeks
18
followed up
18 wk

Good to know: A trial at rehabilitation centres in Bangladesh.

Hossain KMA, Hero MH, Afroze M, et al. Brain and Behavior, 2026 · Read the paper ↗

How this study worked

Shockwave +physio40 peopleAcu-TENS +physio40 peoplePhysio alone40 people
People were assigned to the groups by lot. Each dot is one person.

What happened

Arm movement after a stroke

Fugl–Meyer arm score, 0–66 · higher means more movement

Shockwave + physioAcu-TENS + physioPhysio alone

All three groups regained arm movement. The shockwave group gained the most: about 17 points by week 18, compared with about 13 with Acu-TENS and 9 with physiotherapy alone.
Show the numbers
GroupStartWeek 6Week 18
Shockwave + physio17.8231.2435.04
Acu-TENS + physio17.9528.7831.43
Physio alone18.6625.9727.81

The treatment

Shockwave + physio

Radial, three times a week for 6 weeks

Radial wavesSpread out from the skin; strongest near the surface
Sessions
18, three a week
Pulses
1,500 per muscle
Strength
0.030mJ/mm² · 5 per second
Numbing
Not mentioned
Device
Not named in the paper
Everyone also got
Usual physiotherapy, 40–60 minutes a session

Compared with: Acu-TENS (acupoint stimulation) with physiotherapy, or physiotherapy alone

Settings are what each study used, not a prescription.

Who took part

120 people recovering from stroke, allocated 40 per group; 115 completed post-intervention and 108 follow-up assessment. Selected rehabilitation centers in Bangladesh.

Shockwave + physio40 people
Acu-TENS + physio40 people
Physio alone40 people

Side effects

Side effects were mild and short-lived.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

120 people recovering from stroke, allocated 40 per group; 115 completed post-intervention and 108 follow-up assessment. Selected rehabilitation centers in Bangladesh.

Radial ESWT plus usual physiotherapy40enrolled

Forty allocated per group; the report gives 115 post-intervention and 108 follow-up completers overall but not per-arm analyzed denominators in displayed outcome tables.

Acupoint TENS plus usual physiotherapy40enrolled

Forty allocated per group; the report gives 115 post-intervention and 108 follow-up completers overall but not per-arm analyzed denominators in displayed outcome tables.

Usual physiotherapy alone40enrolled

Forty allocated per group; the report gives 115 post-intervention and 108 follow-up completers overall but not per-arm analyzed denominators in displayed outcome tables.

Upper-limb MAS: between-group difference in change at week 64 reported outcomes
01
Change from baseline to week 6

Upper-limb MAS: between-group difference in change at week 6

Modified Ashworth Scale (MAS), 0–5 analysis score MAS points

MD-0.73CI 95% -1.05 to -0.4

ESWT—UPT, difference in change

Mixed between-group analysis; adjustment details as stated in Table 5

-1.2Equal results 00.1

The reported interval excludes no difference and favors the ESWT-containing group in the stated direction.

Analysis details and source

This is a between-group contrast in change from baseline, not a within-arm treatment effect. Table 5 reports 95% CIs. Per-arm follow-up denominators are not supplied in the displayed table; n is left null.

02
Change from baseline to week 18

Upper-limb MAS: between-group difference in change at week 18

Modified Ashworth Scale (MAS), 0–5 analysis score MAS points

MD-0.7CI 95% -1.02 to -0.38

ESWT—UPT, difference in change

Mixed between-group analysis; adjustment details as stated in Table 5

-1.1Equal results 00.1

The reported interval excludes no difference and favors the ESWT-containing group in the stated direction.

Analysis details and source

This is a between-group contrast in change from baseline, not a within-arm treatment effect. Table 5 reports 95% CIs. Per-arm follow-up denominators are not supplied in the displayed table; n is left null.

03
Change from baseline to week 6

Lower-limb MAS: between-group difference in change at week 6

Modified Ashworth Scale (MAS), 0–5 analysis score MAS points

MD-0.38CI 95% -0.71 to -0.04

ESWT—UPT, difference in change

Mixed between-group analysis; adjustment details as stated in Table 5

-0.8Equal results 00.1

The reported interval excludes no difference and favors the ESWT-containing group in the stated direction.

Analysis details and source

This is a between-group contrast in change from baseline, not a within-arm treatment effect. Table 5 reports 95% CIs. Per-arm follow-up denominators are not supplied in the displayed table; n is left null.

04
Change from baseline to week 18

Lower-limb MAS: between-group difference in change at week 18

Modified Ashworth Scale (MAS), 0–5 analysis score MAS points

MD-0.33CI 95% -0.63 to -0.02

ESWT—UPT, difference in change

Mixed between-group analysis; adjustment details as stated in Table 5

-0.7Equal results 00.1

The reported interval excludes no difference and favors the ESWT-containing group in the stated direction.

Analysis details and source

This is a between-group contrast in change from baseline, not a within-arm treatment effect. Table 5 reports 95% CIs. Per-arm follow-up denominators are not supplied in the displayed table; n is left null.

Upper-limb Fugl–Meyer Assessment: between-group difference in change at week 62 reported outcomes
05
Change from baseline to week 6

Upper-limb Fugl–Meyer Assessment: between-group difference in change at week 6

Fugl–Meyer Assessment, upper limb (FMA-U/L) FMA points

MD6.11CI 95% 3.31 to 8.91

ESWT—UPT, difference in change

Mixed between-group analysis; adjustment details as stated in Table 5

-1.1Equal results 010

The reported interval excludes no difference and favors the ESWT-containing group in the stated direction.

Analysis details and source

This is a between-group contrast in change from baseline, not a within-arm treatment effect. Table 5 reports 95% CIs. Per-arm follow-up denominators are not supplied in the displayed table; n is left null.

06
Change from baseline to week 18

Upper-limb Fugl–Meyer Assessment: between-group difference in change at week 18

Fugl–Meyer Assessment, upper limb (FMA-U/L) FMA points

MD8.07CI 95% 5.36 to 10.77

ESWT—UPT, difference in change

Mixed between-group analysis; adjustment details as stated in Table 5

-1.3Equal results 012.1

The reported interval excludes no difference and favors the ESWT-containing group in the stated direction.

Analysis details and source

This is a between-group contrast in change from baseline, not a within-arm treatment effect. Table 5 reports 95% CIs. Per-arm follow-up denominators are not supplied in the displayed table; n is left null.

Lower-limb Fugl–Meyer Assessment: between-group difference in change at week 62 reported outcomes
07
Change from baseline to week 6

Lower-limb Fugl–Meyer Assessment: between-group difference in change at week 6

Fugl–Meyer Assessment, lower limb (FMA-L/L) FMA points

MD2.7CI 95% 0.79 to 4.61

ESWT—UPT, difference in change

Mixed between-group analysis; adjustment details as stated in Table 5

-0.6Equal results 05.2

The reported interval excludes no difference and favors the ESWT-containing group in the stated direction.

Analysis details and source

This is a between-group contrast in change from baseline, not a within-arm treatment effect. Table 5 reports 95% CIs. Per-arm follow-up denominators are not supplied in the displayed table; n is left null.

08
Change from baseline to week 18

Lower-limb Fugl–Meyer Assessment: between-group difference in change at week 18

Fugl–Meyer Assessment, lower limb (FMA-L/L) FMA points

MD3.14CI 95% 1.24 to 5.03

ESWT—UPT, difference in change

Mixed between-group analysis; adjustment details as stated in Table 5

-0.6Equal results 05.6

The reported interval excludes no difference and favors the ESWT-containing group in the stated direction.

Analysis details and source

This is a between-group contrast in change from baseline, not a within-arm treatment effect. Table 5 reports 95% CIs. Per-arm follow-up denominators are not supplied in the displayed table; n is left null.

Stroke-Specific Quality of Life: between-group difference in change at week 62 reported outcomes
09
Change from baseline to week 6

Stroke-Specific Quality of Life: between-group difference in change at week 6

Stroke-Specific Quality of Life (SS-QOL) SS-QOL points

MD11.64CI 95% 3.03 to 20.25

ESWT—UPT, difference in change

Mixed between-group analysis; adjustment details as stated in Table 5

-2.4Equal results 022.7

The reported interval excludes no difference and favors the ESWT-containing group in the stated direction.

Analysis details and source

This is a between-group contrast in change from baseline, not a within-arm treatment effect. Table 5 reports 95% CIs. Per-arm follow-up denominators are not supplied in the displayed table; n is left null.

10
Change from baseline to week 18

Stroke-Specific Quality of Life: between-group difference in change at week 18

Stroke-Specific Quality of Life (SS-QOL) SS-QOL points

MD11.61CI 95% 4.81 to 18.42

ESWT—UPT, difference in change

Mixed between-group analysis; adjustment details as stated in Table 5

-2.2Equal results 020.6

The reported interval excludes no difference and favors the ESWT-containing group in the stated direction.

Analysis details and source

This is a between-group contrast in change from baseline, not a within-arm treatment effect. Table 5 reports 95% CIs. Per-arm follow-up denominators are not supplied in the displayed table; n is left null.

10-Meter Walk Test time: between-group difference in change at week 62 reported outcomes
11
Change from baseline to week 6

10-Meter Walk Test time: between-group difference in change at week 6

10-Meter Walk Test (10MWT) seconds

MD-2.02CI 95% -5.14 to 1.1

ESWT—UPT, difference in change

Mixed between-group analysis; adjustment details as stated in Table 5

-5.9Equal results 01.8

The confidence interval includes no difference; this contrast is not statistically significant by the reported interval.

Analysis details and source

This is a between-group contrast in change from baseline, not a within-arm treatment effect. Table 5 reports 95% CIs. Per-arm follow-up denominators are not supplied in the displayed table; n is left null.

12
Change from baseline to week 18

10-Meter Walk Test time: between-group difference in change at week 18

10-Meter Walk Test (10MWT) seconds

MD-2.5CI 95% -5.48 to 0.48

ESWT—UPT, difference in change

Mixed between-group analysis; adjustment details as stated in Table 5

-6.2Equal results 01.2

The confidence interval includes no difference; this contrast is not statistically significant by the reported interval.

Analysis details and source

This is a between-group contrast in change from baseline, not a within-arm treatment effect. Table 5 reports 95% CIs. Per-arm follow-up denominators are not supplied in the displayed table; n is left null.

Modified Tardieu Scale (MTS), R2−R1 angle4 reported outcomes
13
Week 6 from baseline

Upper-limb MTS R2−R1 angle, week 6

Modified Tardieu Scale (MTS), R2−R1 angle degrees; mean difference (95% CI)

MD0.82CI 95% -0.26 to 1.91

ESWT+UPT versus UPT; difference in change

-0.5Equal results 02.2

For upper limb at week 6, ESWT+UPT versus UPT was not statistically significant (CI includes zero). The table also reports ESWT versus Acu-TENS MD 1.23 (95% CI 0.08 to 2.38) and Acu-TENS versus UPT MD -0.41 (95% CI -1.59 to 0.76).

Analysis details and source

The contrast is the between-group difference in change; estimates are reproduced as printed. Six-week intervals include zero; do not infer equivalence.

14
Week 18 from baseline

Upper-limb MTS R2−R1 angle, week 18

Modified Tardieu Scale (MTS), R2−R1 angle degrees; mean difference (95% CI)

MD0.75CI 95% -0.39 to 1.89

ESWT+UPT versus UPT; difference in change

-0.7Equal results 02.2

For upper limb at week 18, ESWT+UPT versus UPT was not statistically significant (CI includes zero). The table also reports ESWT versus Acu-TENS MD 1.07 (95% CI -0.14 to 2.28) and Acu-TENS versus UPT MD -0.32 (95% CI -1.53 to 0.89).

Analysis details and source

The contrast is the between-group difference in change; estimates are reproduced as printed. Six-week intervals include zero; do not infer equivalence.

15
Week 6 from baseline

Lower-limb MTS R2−R1 angle, week 6

Modified Tardieu Scale (MTS), R2−R1 angle degrees; mean difference (95% CI)

MD1.42CI 95% -0.22 to 3.06

ESWT+UPT versus UPT; difference in change

-0.6Equal results 03.5

For lower limb at week 6, ESWT+UPT versus UPT was not statistically significant (CI includes zero). The table also reports ESWT versus Acu-TENS MD 0.47 (95% CI -1.22 to 2.12) and Acu-TENS versus UPT MD 0.95 (95% CI -0.77 to 2.67).

Analysis details and source

The contrast is the between-group difference in change; estimates are reproduced as printed. Six-week intervals include zero; do not infer equivalence.

16
Week 18 from baseline

Lower-limb MTS R2−R1 angle, week 18

Modified Tardieu Scale (MTS), R2−R1 angle degrees; mean difference (95% CI)

MD2.4CI 95% 0.7 to 4.09

ESWT+UPT versus UPT; difference in change

-0.5Equal results 04.6

For lower limb at week 18, ESWT+UPT versus UPT was statistically significant as reported by the source. The table also reports ESWT versus Acu-TENS MD 0.47 (95% CI -1.17 to 2.12) and Acu-TENS versus UPT MD 1.92 (95% CI 0.15 to 3.69).

Analysis details and source

The contrast is the between-group difference in change; estimates are reproduced as printed. Six-week intervals include zero; do not infer equivalence.

How treatment was delivered
Radial ESWT device/modality

Radial extracorporeal shock waves; device name not found in reported intervention details.

ESWT parameters

5 Hz; 0.030 mJ/mm²; 1,500 shocks per target muscle belly; midpoint of affected upper- and lower-limb muscle bellies; 30-minute session.

Session schedule

Three sessions weekly for six weeks; 18 sessions total. ESWT and UPT were delivered together in the ESWT group.

Comparator co-intervention

Standardized usual physiotherapy 40–60 minutes/session, including flexibility, ROM, strengthening, trunk control, mobility, balance, gait and task-specific activities.

Acu-TENS comparator arm

100 Hz square wave, 0.2 ms pulse width, intensity 2–3× sensory threshold without visible contraction; 40×40-mm electrodes at four listed acupoints; 30 minutes/session.

HARMS & TOLERABILITY

Thirteen participants reported minor adverse events: 8 across ESWT or Acu-TENS groups and 5 in UPT. In experimental groups, 5 experienced transient muscle soreness or mild increased spasticity resolving within 1–2 days; 3 reported brief fatigue or slight dizziness during exercise. Control reports temporary stiffness/mild discomfort. No serious adverse events were reported.

LIMITS OF THE ANALYSIS

The authors note that recruitment in selected rehabilitation centers in Bangladesh may limit generalizability.

Follow-up ended at 18 weeks, so longer-term outcomes are unknown.

Participants and therapists could not be blinded; potential performance bias remains.

Overall attrition is reported (120 enrolled, 115 post-intervention, 108 follow-up), but the displayed outcomes do not supply timepoint-specific arm denominators.

The authors state that no economic evaluation was performed.

Supplementary Materials 1–3 referenced in results were unavailable in retrieved XML.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • The authors note that recruitment in selected rehabilitation centers in Bangladesh may limit generalizability.
  • Follow-up ended at 18 weeks, so longer-term outcomes are unknown.
  • Participants and therapists could not be blinded; potential performance bias remains.
  • Overall attrition is reported (120 enrolled, 115 post-intervention, 108 follow-up), but the displayed outcomes do not supply timepoint-specific arm denominators.
  • The authors state that no economic evaluation was performed.
  • Supplementary Materials 1–3 referenced in results were unavailable in retrieved XML.
Research review

Source-linked critical reading

Randomized comparative clinical trial

Reading depthMaterial consulted
Technical source record

Full article XML read. All 38 sections, six structured tables with footnotes, and Figure 1 caption were reviewed; raw XML contains six table-wrap elements, matching parsed extraction. Supplementary materials 1–3 were referenced but not present. Figure image pixels were not locally available.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design

Multicenter, three-arm randomized controlled trial with assessor blinding. Participants received 18 sessions over six weeks; assessment was at baseline, six weeks and 18 weeks.

Participants

120 participants were enrolled and equally allocated (40 per group); 115 completed post-intervention assessment and 108 completed follow-up. Participants were recovering from stroke at selected rehabilitation centers in Bangladesh. Mean stroke duration at baseline was approximately 5.1–5.4 months across groups.

Interventions

All groups received standardized usual physiotherapy (UPT), 40–60 minutes per session, three sessions weekly for six weeks. The ESWT group also received radial ESWT: 5 Hz, 0.030 mJ/mm², 1,500 shocks per targeted muscle belly, 30 minutes per session. Acu-TENS group received 100 Hz square-wave stimulation, 0.2 ms pulse width, intensity 2–3 times sensory threshold without visible contraction, 40×40-mm electrodes at four WHO-listed acupoints, 30 minutes per session. Each intervention lasted 18 sessions. Six experienced physiotherapists delivered the interventions.

Comparators

UPT alone was the control. The active adjuncts were ESWT+UPT and Acu-TENS+UPT. The comparison estimates the added treatment package; it does not separate the adjunct from attention or contact time.

Outcomes

Primary outcomes included upper- and lower-limb MAS and Modified Tardieu Scale (MTS); motor function used upper- and lower-limb Fugl–Meyer Assessment (FMA). Secondary outcomes were Stroke-Specific Quality of Life (SS-QOL) and 10-Meter Walk Test (10MWT). Assessments occurred at baseline, week 6 and week 18. The article reports change contrasts with 95% CIs in Table 5 and repeated-measures interactions in Table 6. A primary outcome was omitted from the earlier extraction: the Modified Tardieu Scale (MTS), reported as R2−R1 angle. At week 18, lower-limb MTS favored ESWT+UPT versus UPT (MD 2.40°, 95% CI 0.70 to 4.09) and Acu-TENS+UPT versus UPT (1.92°, 0.15 to 3.69); six-week contrasts included zero. Upper-limb week-6 and week-18 ESWT-versus-UPT intervals also included zero.

Between-group findings

Compared with UPT, ESWT+UPT showed greater change at week 18 in upper-limb MAS (MD −0.70, 95% CI −1.02 to −0.38), lower-limb MAS (−0.33, −0.63 to −0.02), upper-limb FMA (+8.07, 5.36 to 10.77), lower-limb FMA (+3.14, 1.24 to 5.03), SS-QOL (+11.61, 4.81 to 18.42), and lower-limb MTS R2−R1 angle (+2.40°, 0.70 to 4.09). The 10MWT contrast was not statistically significant (−2.50 s, −5.48 to 0.48), despite a significant direct ESWT-versus-Acu-TENS contrast (−2.76 s, −5.18 to −0.34). ESWT versus Acu-TENS differences generally included the null; upper-limb FMA at week 18 did not (MD +3.74, 0.85 to 6.64).

Harms

13 participants reported minor adverse events: 8 across the two experimental groups and 5 in UPT. In experimental groups, 5 reported transient muscle soreness or mild increased spasticity resolving within 1–2 days; 3 reported brief fatigue or slight dizziness during exercise. The UPT group reports temporary stiffness or mild discomfort. No serious adverse events were reported.

Limitations

Authors note selected Bangladeshi rehabilitation centers, no follow-up beyond 18 weeks, inability to blind participants or therapists, uncertainty in target-muscle localization despite standardized landmarks/palpation, and no economic evaluation. The paper reports 120 enrolled, 115 post-treatment and 108 at follow-up; the displayed table headers retain n=40 and do not expose outcome-specific follow-up denominators. Supplements 1–3 are cited but absent from retrieved XML. Figure 1 is a participant-flow diagram; raster was not locally available.

Applicability

The trial suggests possible added benefits for selected impairment, motor and quality-of-life measures when radial ESWT is added to physiotherapy. Walking-time between-group evidence is less certain. Results apply to this selected post-stroke sample and six-week treatment; they do not establish long-term benefit or overall superiority over Acu-TENS.

Further research

Authors recommend larger, diverse multicenter trials with longer follow-up, neurophysiological measures and cost-effectiveness evaluation. Future analyses should report clear per-outcome denominators and prespecified clinically meaningful differences.

THE ORIGINAL SOURCE

Read the original article.

Shockwave Therapy or Acupoint Stimulation Combined With Physiotherapy for Spasticity and Motor Function in Post-Stroke Recovery: A Randomized Controlled Trial.

Hossain KMA, Hero MH, Afroze M, Hossain S, Reza MAI, Hossain T, Galeb AH, Rikti JF, Bari MU, Datta A. · Brain and behavior · 2026

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →